Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

FDA Approves New Pfizer Biosimilar

Business Wire December 13, 2017

Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccine’s Immunogenicity

Business Wire December 13, 2017

Servier et Pfizer publient des résultats préliminaires de deux essais cliniques de Phase I indiquant un taux élevé de rémission complète obtenus avec UCART19 dans le traitement de la leucémie aigue lymphoblastique de l’adulte et de l’enfant

Business Wire December 12, 2017

Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials

Business Wire December 12, 2017

U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months

Business Wire December 12, 2017

Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire December 11, 2017

Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer

Business Wire December 8, 2017

Pfizer Inc. Announces (i) Private Exchange Offer for its 6.500 per cent. Notes due 2038 Open to Certain Investors and Related Tender Offer Open to All Investors and (ii) Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Conse

Business Wire December 7, 2017

Spark Therapeutics and Pfizer Announce Publication in The New England Journal of Medicine of Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Hemophilia B

GlobeNewswire December 6, 2017

Updated Data from Phase 3 Trial of IBRANCE® (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival

Business Wire December 6, 2017

Bristol-Myers Squibb and Pfizer Alliance Urge People to ‘Tune in to AFib, Take Note of Stroke Risk’

Business Wire December 5, 2017

Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific Region

Business Wire December 1, 2017

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Benzinga.com  November 30, 2017

A Lazarus Act For This Pharma ETF

Benzinga.com  November 29, 2017

Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

PR Newswire November 28, 2017

Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer

PR Newswire November 28, 2017

Investor Expectations to Drive Momentum within Intel, Pfizer, CenturyLink, Marathon Oil, Applied Materials, and AK Steel Holding — Discovering Underlying Factors of Influence

GlobeNewswire November 27, 2017

Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

PR Newswire November 21, 2017

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Business Wire November 16, 2017

Pfizer Names Albert Bourla Chief Operating Officer

Business Wire November 13, 2017